European Association of Health Law's Interest Group on Supranational Biolaw

The aim of the EAHL Interest Group on Supranational Biolaw is to promote European health law, especially in its European-level dimension. It has three types of activities that correspond to the activities of European Association of Health Law (EAHL). They are conducted specifically regarding the Supranational European dimension of biolaw and thus go beyond comparisons of national biolaws.
1/ Research
- Promote the Supranational European dimension of biolaw;
- Organise scientific events;
- Launch joint research projects on selected topics of common interest to advance legal reflection;
- Achieve international publications.
2/ Training
- Organise training events,
- Facilitate teaching exchanges relating to Supranational Biolaw, and guest lectures and seminars.
- Provide training or events to society at large.
3/ Networking
- Members mobilise their respective networks to promote access of young researchers to positions in Supranational Biolaw, and for visibility

The EAHL Interest Group on Supranational Biolaw in interested in all EU activities related to European Health Law, especially European Biolaw.
Our activities mainly focus on the European Health strategy, including especially the European health Union and the pharmaceutical strategy, but also the research strategy Europe 2020.
The main legislations/policies we are interested in are:
- "Building a European Health Union: Reinforcing the EU’s resilience for cross-border health threats" COM(2020) 724 final
- "Pharmaceutical strategy for Europe" COM(2020) 761 final
- Regulation (EU) 2021/522 establishing a Programme for the Union’s action in the field of health (‘EU4Health Programme’) for the period 2021-2027
- "the Global Approach to Research and Innovation" COM(2021) 252 final
- Directive 2001/83/EC and its amendments
- Directive 2002/98/EC setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components
- Directive 2004/23/EC on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells
- Directive 2010/45/EU on standards of quality and safety of human organs intended for transplantation
- Directive 2009/41/EC on the contained use of genetically modified micro-organisms
- Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms
- Regulation (EU) 2017/746 on in vitro diagnostic medical devices
- Regulation (EU) 2017/745 on medical devices
- Council Regulation (EU) No 557/2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking
- Regulation (EC) No 1394/2007 on advanced therapy medicinal products
- Regulations (EC) No 1901/2006 and 1902/2006 on medicinal products for paediatric use
- Regulation (EC) No 141/2000 on orphan medicinal products
- Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use
- Directive 2011/62/EU on falsified medicinal products
- Regulation (EU) 2021/2282 on health technology assessment
- Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare
- Directive 98/44/EC on the legal protection of biotechnological inventions
- Regulation (EU) No 1257/2012 implementing enhanced cooperation in the area of the creation of unitary patent protection
- Regulation (EU) 2016/679 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data
- Council Directive 89/105/EEC relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems

https://eahl.eu/eahl-interest-group-supranational-biolaw

2

0.5

No lobbyists with EP accreditations

None declared

Data not provided by Register Secretariat due to GDPR

Data not provided by Register Secretariat due to GDPR

Think tanks and research institutions